Netherlands Cancer Institute
@nkinl.bsky.social
The Netherlands Cancer Institute (NKI): at the international forefront of cancer research and treatment for over 100 years.
Pinned
Follow our NKI community go.bsky.app/5EK1wtK
Pastry chef Müller brightened our day by delivering no fewer than 2,000 cream puffs for employees of the Netherlands Cancer Institute 🧁 Each year, Müller runs a campaign in which a donation is made to the Mike Multi Foundation for every cream puff sold.
Thank you!
Thank you!
February 5, 2026 at 12:08 PM
Pastry chef Müller brightened our day by delivering no fewer than 2,000 cream puffs for employees of the Netherlands Cancer Institute 🧁 Each year, Müller runs a campaign in which a donation is made to the Mike Multi Foundation for every cream puff sold.
Thank you!
Thank you!
Out now in @natureportfolio.nature.com: PARM reveals gene regulation is far more predictable than thought. Lightweight, cell‑type specific, and experimentally validated. Enables functional prediction of regulatory mutations with just one dish of cells + one day of compute.
➡️ doi.org/10.1038/s415...
➡️ doi.org/10.1038/s415...
February 4, 2026 at 4:27 PM
Out now in @natureportfolio.nature.com: PARM reveals gene regulation is far more predictable than thought. Lightweight, cell‑type specific, and experimentally validated. Enables functional prediction of regulatory mutations with just one dish of cells + one day of compute.
➡️ doi.org/10.1038/s415...
➡️ doi.org/10.1038/s415...
It’s amazing how much one can discover about a single protein. In the case of PhD candidate Niels Keijzer, that protein is USP1. During his PhD he unraveled several of its secrets ➡️ www.nki.nl/news-events/...
February 2, 2026 at 4:51 PM
It’s amazing how much one can discover about a single protein. In the case of PhD candidate Niels Keijzer, that protein is USP1. During his PhD he unraveled several of its secrets ➡️ www.nki.nl/news-events/...
Reposted by Netherlands Cancer Institute
Why do patients with liver metastases respond so poorly to cancer immunotherapy?
Here we find a new immunological mechanism in MMR-d cancers centering on IL-18 and γδ T cells.👇 www.cell.com/cell-reports... @cp-cellrepmed.bsky.social
Here we find a new immunological mechanism in MMR-d cancers centering on IL-18 and γδ T cells.👇 www.cell.com/cell-reports... @cp-cellrepmed.bsky.social
Liver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer
van Renterghem et al. investigate the impact of liver metastases on immunity in MMR-d/MSI-hi
patients treated with ICB. They show that IL18 activates liver-derived Vδ1+ T cells
and predicts ICB benefi...
www.cell.com
January 27, 2026 at 2:29 PM
Why do patients with liver metastases respond so poorly to cancer immunotherapy?
Here we find a new immunological mechanism in MMR-d cancers centering on IL-18 and γδ T cells.👇 www.cell.com/cell-reports... @cp-cellrepmed.bsky.social
Here we find a new immunological mechanism in MMR-d cancers centering on IL-18 and γδ T cells.👇 www.cell.com/cell-reports... @cp-cellrepmed.bsky.social
Congratulations @sarahmoser.bsky.social 🎊
Excited to share that I received this year's Antoni van Leeuwenhoek (AVL) award for my PhD research 🧬
A big thank you to my PhD mentor @josjonkers.bsky.social and everyone else who has contributed to this work at @nkinl.bsky.social 🌟
www.nki.nl/news-events/...
A big thank you to my PhD mentor @josjonkers.bsky.social and everyone else who has contributed to this work at @nkinl.bsky.social 🌟
www.nki.nl/news-events/...
Sarah Moser wins the Antoni van Leeuwenhoek Award 2025 | Netherlands Cancer Institute
Researcher Sarah Moser has received the Antoni van Leeuwenhoek Award 2025 today. In the research group led by Jos Jonkers, she studied how cells repair their DNA and what happens when this repair process fails.
www.nki.nl
January 22, 2026 at 10:08 AM
Congratulations @sarahmoser.bsky.social 🎊
Good news for many: women with breast cancer who receive silicone implants don’t have a higher risk of symptoms linked to Breast Implant Illness, concludes PhD candidate Jonathan Spoor based on a large Dutch study involving over 6,000 women ➡️ www.nki.nl/news-events/...
January 12, 2026 at 4:07 PM
Good news for many: women with breast cancer who receive silicone implants don’t have a higher risk of symptoms linked to Breast Implant Illness, concludes PhD candidate Jonathan Spoor based on a large Dutch study involving over 6,000 women ➡️ www.nki.nl/news-events/...
🎓 Our immune system has an effect on the tumor, and vice versa. It is more active in metastatic cancer. PhD candidate Noor Bakker sees major differences, especially in patients with triple-negative breast cancer. www.nki.nl/news-events/...
January 9, 2026 at 11:40 AM
🎓 Our immune system has an effect on the tumor, and vice versa. It is more active in metastatic cancer. PhD candidate Noor Bakker sees major differences, especially in patients with triple-negative breast cancer. www.nki.nl/news-events/...
As per January German-English scientist Natalie Scholes (32) will start her own research group at the Netherlands Cancer Institute! ➡️ nki.nl/news-events/news/chemical-matchmaker-in-search-of-societal-impact-natalie-scholes-starts-research-group-at-the-netherlands-cancer-institute/
#NKI #research
#NKI #research
January 8, 2026 at 2:00 PM
As per January German-English scientist Natalie Scholes (32) will start her own research group at the Netherlands Cancer Institute! ➡️ nki.nl/news-events/news/chemical-matchmaker-in-search-of-societal-impact-natalie-scholes-starts-research-group-at-the-netherlands-cancer-institute/
#NKI #research
#NKI #research
🎉 Group Leader Leila Akkari @leilaakkari.bsky.social has been appointed Professor of Cancer-Immune Interactions at Leiden University. Congratulations Leila! www.nki.nl/news-events/...
January 6, 2026 at 2:24 PM
🎉 Group Leader Leila Akkari @leilaakkari.bsky.social has been appointed Professor of Cancer-Immune Interactions at Leiden University. Congratulations Leila! www.nki.nl/news-events/...
Reposted by Netherlands Cancer Institute
🐭 In vivo veritas 🐭
Now out in Nature Genetics: @josjonkers.bsky.social and I describe currently available mouse models of BRCA1/2 and their roles in understanding BRCA1/2 biology, particularly in normal development, tumor suppression and therapy response.
www.nature.com/articles/s41...
Now out in Nature Genetics: @josjonkers.bsky.social and I describe currently available mouse models of BRCA1/2 and their roles in understanding BRCA1/2 biology, particularly in normal development, tumor suppression and therapy response.
www.nature.com/articles/s41...
Insights from three decades of BRCA1/2 modeling in mice - Nature Genetics
This Perspective highlights the insights into the biology of BRCA1/2 afforded by mouse models and patient-derived tumor xenografts and emphasizes their value in addressing unresolved questions and pre...
www.nature.com
January 6, 2026 at 12:30 PM
🐭 In vivo veritas 🐭
Now out in Nature Genetics: @josjonkers.bsky.social and I describe currently available mouse models of BRCA1/2 and their roles in understanding BRCA1/2 biology, particularly in normal development, tumor suppression and therapy response.
www.nature.com/articles/s41...
Now out in Nature Genetics: @josjonkers.bsky.social and I describe currently available mouse models of BRCA1/2 and their roles in understanding BRCA1/2 biology, particularly in normal development, tumor suppression and therapy response.
www.nature.com/articles/s41...
✨ Happy New Year! ✨
As we step into 2026, we want to thank all of you for being part of our journey in 2025. Together, we’ve achieved incredible milestones we’re looking forward to continuing to make a difference in cancer research. Let’s make 2026 a year of collaboration, innovation and inspiration
As we step into 2026, we want to thank all of you for being part of our journey in 2025. Together, we’ve achieved incredible milestones we’re looking forward to continuing to make a difference in cancer research. Let’s make 2026 a year of collaboration, innovation and inspiration
January 1, 2026 at 12:40 PM
✨ Happy New Year! ✨
As we step into 2026, we want to thank all of you for being part of our journey in 2025. Together, we’ve achieved incredible milestones we’re looking forward to continuing to make a difference in cancer research. Let’s make 2026 a year of collaboration, innovation and inspiration
As we step into 2026, we want to thank all of you for being part of our journey in 2025. Together, we’ve achieved incredible milestones we’re looking forward to continuing to make a difference in cancer research. Let’s make 2026 a year of collaboration, innovation and inspiration
Inspired by an initiative from OLVG Hospital, team leaders, managers and directors stepped into care roles during Operation Oliebol including Henri van Luenen & @vanrheenenlab.bsky.social
Not because they had to, but to support colleagues working on New Year’s Eve
Not because they had to, but to support colleagues working on New Year’s Eve
December 31, 2025 at 12:59 PM
Inspired by an initiative from OLVG Hospital, team leaders, managers and directors stepped into care roles during Operation Oliebol including Henri van Luenen & @vanrheenenlab.bsky.social
Not because they had to, but to support colleagues working on New Year’s Eve
Not because they had to, but to support colleagues working on New Year’s Eve
🎓 There are more and more options for breast-conserving treatment for breast cancer patients. However, PhD candidate Eva Heeling shows that aren’t offered the same options across all hospitals. More: www.nki.nl/news-events/...
December 17, 2025 at 11:28 AM
🎓 There are more and more options for breast-conserving treatment for breast cancer patients. However, PhD candidate Eva Heeling shows that aren’t offered the same options across all hospitals. More: www.nki.nl/news-events/...
Eleven research teams at the Netherlands Cancer Institute are starting new cancer projects thanks to funding from the Dutch Cancer Society. From personalized therapies to smarter detection, these projects push science closer to patients. Thank you KWF ❤️💙
Learn more: www.nki.nl/news-events/...
Learn more: www.nki.nl/news-events/...
December 16, 2025 at 2:45 PM
Eleven research teams at the Netherlands Cancer Institute are starting new cancer projects thanks to funding from the Dutch Cancer Society. From personalized therapies to smarter detection, these projects push science closer to patients. Thank you KWF ❤️💙
Learn more: www.nki.nl/news-events/...
Learn more: www.nki.nl/news-events/...
Corticosteroids may re-sensitize metastatic HR+ breast cancer to endocrine therapy by mimicking cortisol-driven fasting responses. Our study, published in Nature, shows a potential new use for a cheap and widely used drug class. ➡️ www.nki.nl/news-events/...
December 10, 2025 at 4:30 PM
Corticosteroids may re-sensitize metastatic HR+ breast cancer to endocrine therapy by mimicking cortisol-driven fasting responses. Our study, published in Nature, shows a potential new use for a cheap and widely used drug class. ➡️ www.nki.nl/news-events/...
Cells appear as chaotic as a big city, but transcription factors behave like packages and are usually delivered smoothly. PhD candidate Jos Meeussen was able to track-and-trace them under his microscope: www.nki.nl/news-events/...
December 3, 2025 at 10:32 AM
Cells appear as chaotic as a big city, but transcription factors behave like packages and are usually delivered smoothly. PhD candidate Jos Meeussen was able to track-and-trace them under his microscope: www.nki.nl/news-events/...
Reposted by Netherlands Cancer Institute
💡Welcome to #EULIFEspotlight!
This month we celebrate Henri van Luenen, Director of Operations at @nkinl.bsky.social, who moderated the session “Research security in practice: making space for an honest conversation”, organised by EU-LIFE at the EU Conference on #ResearchSecurity
🔗 bit.ly/4hPXbhw
This month we celebrate Henri van Luenen, Director of Operations at @nkinl.bsky.social, who moderated the session “Research security in practice: making space for an honest conversation”, organised by EU-LIFE at the EU Conference on #ResearchSecurity
🔗 bit.ly/4hPXbhw
November 27, 2025 at 8:21 AM
💡Welcome to #EULIFEspotlight!
This month we celebrate Henri van Luenen, Director of Operations at @nkinl.bsky.social, who moderated the session “Research security in practice: making space for an honest conversation”, organised by EU-LIFE at the EU Conference on #ResearchSecurity
🔗 bit.ly/4hPXbhw
This month we celebrate Henri van Luenen, Director of Operations at @nkinl.bsky.social, who moderated the session “Research security in practice: making space for an honest conversation”, organised by EU-LIFE at the EU Conference on #ResearchSecurity
🔗 bit.ly/4hPXbhw
Joost Agelink van Rentergem received a Vidi grant for research on cognitive impairment ➡️ www.nki.nl/news-events/...
Joost Agelink van Rentergem receives Vidi grant for research on cognit…
www.nki.nl
November 25, 2025 at 6:04 PM
Joost Agelink van Rentergem received a Vidi grant for research on cognitive impairment ➡️ www.nki.nl/news-events/...
Reposted by Netherlands Cancer Institute
Last Thursday I defended my PhD at @erasmusmc.bsky.social Thank you so much to all that joined the defence and to @maxkoppers.bsky.social, @madelonmaurice.bsky.social, Celia Berkers and Vered Raz for the great scientific discussion.
November 24, 2025 at 1:22 PM
Last Thursday I defended my PhD at @erasmusmc.bsky.social Thank you so much to all that joined the defence and to @maxkoppers.bsky.social, @madelonmaurice.bsky.social, Celia Berkers and Vered Raz for the great scientific discussion.
Honored to welcome Prof. Charles Swanton for this year’s Piet Borst Lecture ✨
The afternoon opened with a beautiful cello intermezzo 🎻
Inspiring from start to finish.”
The afternoon opened with a beautiful cello intermezzo 🎻
Inspiring from start to finish.”
November 20, 2025 at 3:16 PM
Honored to welcome Prof. Charles Swanton for this year’s Piet Borst Lecture ✨
The afternoon opened with a beautiful cello intermezzo 🎻
Inspiring from start to finish.”
The afternoon opened with a beautiful cello intermezzo 🎻
Inspiring from start to finish.”
A new @nature.com.web.brid.gy paper by @peeperlab.bsky.social shows that T cells that cling to cancer cells are the most potent killers. These clusters, long overlooked, can be isolated directly from tumors www.nature.com/articles/s41...
Tumour-reactive heterotypic CD8 T cell clusters from clinical samples - Nature
Tumour-reactive CD8+ T cells are enriched in functional clusters with tumour cells and/or antigen-presenting cells and can be isolated and expanded from clinical samples.
www.nature.com
November 20, 2025 at 10:53 AM
A new @nature.com.web.brid.gy paper by @peeperlab.bsky.social shows that T cells that cling to cancer cells are the most potent killers. These clusters, long overlooked, can be isolated directly from tumors www.nature.com/articles/s41...
Reposted by Netherlands Cancer Institute
Our new paper is out in Nature - online today!
Huge congrats to shared first authors Sofía Ibáñez-Molero & Johanna Veldman, the whole team & all collaborators.
📄 Open-access paper: www.nature.com/articles/s41...
Huge congrats to shared first authors Sofía Ibáñez-Molero & Johanna Veldman, the whole team & all collaborators.
📄 Open-access paper: www.nature.com/articles/s41...
Tumour-reactive heterotypic CD8 T cell clusters from clinical samples - Nature
Tumour-reactive CD8+ T cells are enriched in functional clusters with tumour cells and/or antigen-presenting cells and can be isolated and expanded from clinical samples.
www.nature.com
November 19, 2025 at 9:00 PM
Our new paper is out in Nature - online today!
Huge congrats to shared first authors Sofía Ibáñez-Molero & Johanna Veldman, the whole team & all collaborators.
📄 Open-access paper: www.nature.com/articles/s41...
Huge congrats to shared first authors Sofía Ibáñez-Molero & Johanna Veldman, the whole team & all collaborators.
📄 Open-access paper: www.nature.com/articles/s41...
At the end of the rainbow 🌈
📷 Zowi Huinen
📷 Zowi Huinen
November 20, 2025 at 7:37 AM
At the end of the rainbow 🌈
📷 Zowi Huinen
📷 Zowi Huinen
🎓 Patients who survived (non-)Hodgkin lymphoma have a higher risk of cardiovascular diseases or subsequent malignancies. Yvonne Geurts successfully defended her thesis showing that that a better understanding of these risks contributed to improved & risk-based follow-up care. Congratulations Yvonne!
November 23, 2025 at 3:05 PM
🎓 Patients who survived (non-)Hodgkin lymphoma have a higher risk of cardiovascular diseases or subsequent malignancies. Yvonne Geurts successfully defended her thesis showing that that a better understanding of these risks contributed to improved & risk-based follow-up care. Congratulations Yvonne!
Ribosomes are just like people. They are diverse, they can dance, collide, and experience stress. During stress, the translation process plays a key role in the development of cancer, a discovery made by PhD candidate Sofia Ramalho ➡️ www.nki.nl/news-events/... @sofiaramalho.bsky.social
November 19, 2025 at 9:26 AM
Ribosomes are just like people. They are diverse, they can dance, collide, and experience stress. During stress, the translation process plays a key role in the development of cancer, a discovery made by PhD candidate Sofia Ramalho ➡️ www.nki.nl/news-events/... @sofiaramalho.bsky.social